Companies · Biotechnology

LikeMinds, Inc./DE

BOSTON · Biotechnology

Diligence memoA one-page analyst read on LikeMinds, Inc./DE — recommendation, valuation, rhythm, risks.
$6.4M
Total raised · real
2
Rounds
0.2×
Latest step-up
Top 53%
Sector rank · raised
Series A
Latest stage · inferred · Fri May 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

LikeMinds, Inc./DE looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.15× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

LikeMinds, Inc./DE is one of 4291 Biotechnology companies tracked from BOSTON. By capital raised it ranks mid-pack (ahead of 48% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
9
Investors (latest)
2018
Year incorporated
2021-05-28
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2018-09-12 Raised $5.2M (real) Modeled valuation $189M (est)$5.2M$189MSeries A2018Series A · 2021-05-28 Raised $1.1M (real) Modeled valuation $27M (est)$1.1M$27MSeries A2021+$1.1MCumulative $6.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.2M · 2018
Series A extension$1.1M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$26.7M
Base estimate est.
$1.3M
Conservative case
$117.9M
Upside case
$5.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $188.8M · 2018-09-122018Series A · modeled $26.7M · 2021-05-282021
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
5.1 yr
Elapsed time used
5.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
32 mo
Avg between rounds
$2.4M/yr
Capital velocity
7.8 yr
On record since
2018
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.9× of median
This company$6.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$1.1M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$26.7M
Sector median$64.2M

Raised more than 48% of sector peers (real $). Modeled value above 33% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #201 of 216.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $541.9M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $484.6M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)LikeMinds, Inc./DE (this company) Raised $6.4M · modeled $26.7M (est)LikeMinds, Inc./DE
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$541.9M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Taiga Biotechnologies, Inc.Series A$37.9M$484.6M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
LikeMinds, Inc./DE this companySeries A$6.4M$26.7M0.15×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.2M2018-09-12$23.7M$188.8M90%
Series A$1.1M2021-05-28$5.2M$26.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.2M2018-09-12
    • First recorded raise — entered as Series A.
    • 12 investors on this round.
  2. Series A$1.1M2021-05-28
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 4.6× smaller than the prior — bridge or down round.
    • 9 investors on this round.
Intelligence
2024 ~Q1
Modeled next raise · ~32mo cadence
$1.1M
Modeled next size est.range $1.1M$1.8M
0.2×
Last step-up
$2.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Paul G. Sekhri1 other2018-09
Peter G. Savas1 other2018-09
Gary G. Frashier2018-09
Henry G. Brem2018-09
Kenneth G. Rice2018-09
Robert G. Langer2018-09
Robert G. Van Nostrand2018-09
Vicki G. Zikopoulou2021-05
Registry & provenance

LikeMinds, Inc./DE is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1753658
SEC CIK
2018
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Alseres Pharmaceuticals Inc /DeBiotechnologySeed$5.9M$44.4Mnetwork1 shared operator · same sector
Intellistem, Inc.BiotechnologySeries A$6.2M$25.6Msame sector · same stage
MB Holdings 2025, Inc.BiotechnologySeries A$6.2M$23.9Msame sector · same stage
Aveta Biomics, Inc.BiotechnologySeries A$6.2M$24.4Msame sector · same stage
SimBioSys, Inc.BiotechnologySeries A$6.1M$21.9Msame sector · same stage
Amplifi Vascular, Inc.BiotechnologySeries A$6.7M$29.0Msame sector · same stage
Cynaptec Pharmaceuticals, Inc.BiotechnologySeries A$6.0M$21.6Msame sector · same stage
Enquyst Technologies Inc.BiotechnologySeries A$6.0M$20.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Novamind Inc.BiotechnologySeries A$66.5M87%
Novamind Ventures Inc.BiotechnologySeed$78.2M86%
Ideaya Biosciences, Inc.BiotechnologySeries C$3.9B83%
Genome Insight, Inc.BiotechnologySeries A$39.9M83%
Sensearly Inc.BiotechnologySeed$5.7M83%
AstralBio, Inc.BiotechnologyPre-Seed$3.4M83%
Clearmind Medicine Inc.BiotechnologySeed$15.1M83%
Senseonics Holdings, Inc.BiotechnologySeries B$98.8M82%
Frequently asked
How much funding has LikeMinds, Inc./DE raised?
LikeMinds, Inc./DE has raised approximately $6.4M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is LikeMinds, Inc./DE's estimated valuation?
Provath's modeled valuation for LikeMinds, Inc./DE is approximately $26.7M (modeled range $1.3M–$117.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is LikeMinds, Inc./DE at?
LikeMinds, Inc./DE's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri May 28.
What does LikeMinds, Inc./DE do and where is it based?
LikeMinds, Inc./DE operates in the Biotechnology sector, based in BOSTON.
Explore related

See where LikeMinds, Inc./DE sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at LikeMinds, Inc./DE, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.